The objective of this study was to evaluate hypoglycemic effects of Lactobacillus paracasei TD062 on the type 2 diabetes mice treated with the strain at 109， 108 and 107 CFU/mL. Meanwhile， the expression levels of glycogen synthase kinase 3β（GSK-3β） were determined to explore the hypoglycemic mechanism. The results demonstrated that L. paracasei TD062 could ameliorate glucose levels， organ coefficient and body weight. In addition， glucose tolerance and antioxidant capacity were elevated by oral administration of L. paracasei TD062. Furthermore， it was revealed that L. paracasei TD062 downregulated the relative expression levels of GSK-3β， regulated glucose metabolic disorders and ameliorated insulin resistance， thus delaying the development of diabetes. Therefore， L. paracasei TD062 might be applied as a new type of hypoglycemic agent in functional foods.